Postmarket Safety Actions for Novel Oncology Drugs Granted FDA’s Accelerated Approval

JAMA Network Open 2026 Open access

Read full text
Authors: Maryam Mooghali, J D Wallach, Aaron P. Mitchell, Joseph S. Ross, Reshma Ramachandran
DOI: 10.1001/jamanetworkopen.2025.53764
Cited by: 4
References: 5

Abstract

This cross-sectional study examines postmarket safety actions for novel oncology drugs that received accelerated Food and Drug Administration (FDA) approval.

Fields of Study & Subjects

Statistical Methods in Clinical Trials Biomedical Ethics and Regulation Advanced Causal Inference Techniques

Publication details

Journal / source
JAMA Network Open
Publisher
American Medical Association (AMA)
Volume
9
Issue
1
Pages
e2553764–e2553764
Publication date
13 January 2026
Language
EN